In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin.

Authors

Krysta Brown, Department of Internal Medicine, Tower Health/Reading Hospital, West Reading, Pennsylvania, USAFollow
Anthony Donato, Department of Internal Medicine, Tower Health/Reading Hospital, West Reading, Pennsylvania, USAFollow

Document Type

Article

Publication Date

1-3-2023

Abstract

GRADE Study Research Group; Nathan DM, Lachin JM, Buse JB, et al.

Publication Title

Annals of internal medicine

Comments

online ahead of print

Recommended Citation

Brown, K., & Donato, A. (2023). In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin.. Annals of internal medicine https://doi.org/https://doi.org/10.7326/j22-0105